Epsilon Molecular Engineering
Latest round
- Series A
Last raised
- Dec 2020
Total raised
- $3.2M
Investors
- 4
About Epsilon Molecular Engineering
Founded in 2016 and based in Saitama, Japan, Epsilon Molecular Engineering Inc.a Epsilon Molecular Engineering specializes in advanced biomolecular technologies, focusing on VHH antibodies for pharmaceutical and diagnostic applications. They provide innovative solutions to enhance drug development processesEpsilon Molecular Engineering Inc. develops VHH antibodies and has pivoted towards integrating proprietary cDNA display technology for product enhancements. Epsilon Molecular Engineering specializes in the development and application of advanced biomolecular technologies, particularly focusing on VHH antibodies. Their key offerings include the PharmaLogical® Library, a humanized VHH antibody library engineered through proprietary cDNA display technology. This innovative library is central to their high-throughput VHH screening and profiling service known as 'The Month,' which is designed to facilitate the rapid identification and optimization of VHH antibodies for various applications. These efforts primarily support the pharmaceutical, in vitro diagnostics, and research reagent sectors, addressing critical needs in drug development and diagnostic testing.Epsilon Molecular Engineering generates revenue through strategic partnerships and service agreements with its clients in the biomedical field. Transactions typically occur on a business-to-business (B2B) basis, where clients engage the company for specific projects or ongoing research collaborations, often leveraging the PharmaLogical® Library and the associated screening services. The revenue model is structured around contracts that specify deliverables, timelines, and milestones, ensuring transparent engagement with clients. Revenue is derived from project-based fees for customized VHH antibody development or licensing agreements related to their proprietary technologies, focusing on effective solutions for drug discovery and diagnostics.
Who invested in Epsilon Molecular Engineering
4 investors across 2 rounds
See all investors in Epsilon Molecular Engineering
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Epsilon Molecular Engineering
Who invested in Epsilon Molecular Engineering?
Epsilon Molecular Engineering has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Epsilon Molecular Engineering raised?
Epsilon Molecular Engineering has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Epsilon Molecular Engineering last raise money?
Epsilon Molecular Engineering's most recent round on record is a Series A, in Dec 2020.
What does Epsilon Molecular Engineering do?
Founded in 2016 and based in Saitama, Japan, Epsilon Molecular Engineering Inc.
Where is Epsilon Molecular Engineering headquartered?
Epsilon Molecular Engineering is headquartered in Saitama, Japan.
Which VCs invest in companies like Epsilon Molecular Engineering?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Epsilon Molecular Engineering's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Epsilon Molecular Engineering? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.